Quote | BioTime Inc. (NYSE:LCTX)
Last: | $1.155 |
---|---|
Change Percent: | -3.75% |
Open: | $1.22 |
Close: | $1.20 |
High: | $1.23 |
Low: | $1.15 |
Volume: | 704,115 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | BioTime Inc. (NYSE:LCTX)
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development...
Event Scheduled for June 26 and 27, 2024 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation , a non-profit organizati...
Message Board Posts | BioTime Inc. (NYSE:LCTX)
Subject | By | Source | When |
---|---|---|---|
https://www.mdpi.com/2079-7737/12/5/653 | chrismiss_everyday | investorshub | 04/30/2023 11:54:42 AM |
NEWS -- RG6501 (OpRegen®) Phase 1/2a Clinical Results | Paulness | investorshub | 04/26/2023 1:22:54 PM |
April 26, 2023 8:00 AM EDT | chrismiss_everyday | investorshub | 04/26/2023 1:03:46 PM |
A systems biology approach uncovers novel disease mechanisms | chrismiss_everyday | investorshub | 04/21/2023 12:44:56 PM |
ZZZZZZZZZZZZZ | abracky | investorshub | 04/18/2023 3:37:54 PM |
News, Short Squeeze, Breakout and More Instantly...
BioTime Inc. Company Name:
LCTX Stock Symbol:
NYSE Market:
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development...
Event Scheduled for June 26 and 27, 2024 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation , a non-profit organizati...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT0...